Dr. Bardin has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis, Menarini, Ipsen, Pfizer, and Savient.
Unité Rhumatologique des Affections de la Main (URAM) scale: Development and validation of a tool to assess Dupuytren's disease–specific disability
Article first published online: 27 SEP 2011
Copyright © 2011 by the American College of Rheumatology
Arthritis Care & Research
Volume 63, Issue 10, pages 1448–1455, October 2011
How to Cite
Beaudreuil, J., Allard, A., Zerkak, D., Gerber, R. A., Cappelleri, J. C., Quintero, N., Lasbleiz, S., Bernabé, B., Orcel, P., Bardin, T. and URAM Study Group (2011), Unité Rhumatologique des Affections de la Main (URAM) scale: Development and validation of a tool to assess Dupuytren's disease–specific disability. Arthritis Care Res, 63: 1448–1455. doi: 10.1002/acr.20564
- Issue published online: 27 SEP 2011
- Article first published online: 27 SEP 2011
- Accepted manuscript online: 22 JUL 2011 01:22PM EST
- Manuscript Accepted: 9 JUL 2011
- Manuscript Received: 23 SEP 2010
- Pfizer Inc.
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.